A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
复制标题
对改良 FOLFIRINOX 具有持续异常反应的体细胞 BRCA2 突变胰腺腺癌。
DOI：
10.1093/oncolo/oyad315
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Manji,GulamA
中科院分区：
文献类型：
--
作者：
Jamison,JacobK;May,MichaelS;Raufi,AlexanderG;Luk,Lyndon;Wong,Winston;Mundi,PrabhjotS;Manji,GulamA
同源重组修复（HRR）通路缺乏为胰腺癌的治疗开辟了多种途径。伴有HRR缺乏相关基因突变（如brca1、BRCA2和palb2）的患者更容易接受铂类化疗，而在伴有brca1、BRCA2和palb2突变的患者中，PARP抑制剂治疗可延长无进展生存期。本文讨论的病例说明了通过识别胰腺癌中HRR缺乏提供的治疗机会，以及胰腺癌长期幸存者中与治疗和预防中枢神经系统转移相关的挑战。
Homologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency–associated gene mutations such asBRCA1,BRCA2, andPALB2are more susceptible to platinum-based chemotherapies and in those with somaticBRCAmutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associated with treatment and prevention of central nervous system metastases in long-term survivors of pancreatic cancer.